References
- Pasquier E, Kavallaris M, André N. Metronomic chemotherapy: new
rationale for new directions. Nat Rev Clin Oncol 2010;7:455-465.
- Hanahan D, Bergers G, Bergsland E. Less is more, regularly: metronomic
dosing of cytotoxic drugs can target tumor angiogenesis in mice. J
Clin Invest 2000;105:1045-1047
- Wurthwein G, Krumpelmann S, Tillmann B, et al. Population
pharmacokinetic approach to compare oral and iv administration of
etoposide. Anticancer Drugs 1999;10:807-814.
- Kebudi R, Corgun O, Ayan I. Oral etoposide for recurrent/progressive
sarcomas of childhood. Pediatr Blood Cancer 2004;42:320-324.
- Verschuur A, Heng-Mallard MA, Dory-Lautrec P, et al. Metronomic
four-drug regimen has anti-tumor activity in pediatric low-grade
glioma; the results of a phase II clinical trial. Front Pharmacol
2018;27:00950.
- Heng-Mallard MA, Verschuur A, Aschero A, et al. SFCE METRO-01
four-drug metronomic regimen phase II trial for pediatric extracranial
tumor. Pediatr Blood Cancer 2019;66:e27693.
- Sterba J, Valik D, Mudry P, et al. Combined biodifferentiating and
antiangiogenic oral metronomic therapy is feasible and effective in
relapsed solid tumors in children: single-center pilot study.
Onkologie 2006;29:308-313.
- Zapletalova D, André N, Deak L, et al. Metronomic chemotherapy with
the COMBAT regimen in advanced pediatric malignancies: a multicenter
experience. Oncology 2012;82:249-260.
- Kieran MW, Turner CD, Rubin JB, et al. A feasibility trial of
antiangiogenic (metronomic) chemotherapy in pediatric patients with
recurrent or progressive cancer. J Pediatr Hematol Oncol
2005;27:573-581.
- Robison NJ, Campigotto F, Chi SN, et al. A phase II trial of a
multi-agent oral antiangiogenic (metronomic) regimen in children with
recurrent or progressive cancer. Pediatr Blood Cancer 2014;61:636-642.
- Pramanik R, Bakhshi S. Metronomic therapy in pediatric oncology: A
snapshot. Pediatr Blood Cancer 2019;66:e27811.
- Pramanik R, Agarwala S, Gupta YK, et al. Metronomic chemotherapy vs
best supportive care in progressive pediatric solid malignant tumors.
A randomized clinical trial. Jama Oncol 2017;3:1222-1227.
- Malik OS, Raina V, Andre N, et al. Metronomics as maintenance
treatment in oncology: time for chemo-switch. Front Oncol 2014;4:76.
- Schwartz LH, Seymour L, Litiere S, et al. RECIST 1.1 –
Standardisation and disease-specific adaptations: perspectives from
the RECIST Working Group. Eur J Cancer 2016;62:138-145.
- Common Terminology Criteria for Adverse Events (CTCAE) Version5.
Published: November 27. US Department of Health and Human Services,
National Institutes of Health, National Cancer Institute.
- Kanda Y. Investigation of the freely available easy-to-use software
‘EZR’ for medical statistics. Bone Marrow Transplant 2013;48:452-458.
- Bisogno G, De Salvo GL, Bergeron C, et al. Vinorelbine and continuous
low-dose cyclophosphamide as maintenance chemotherapy in patients with
high-risk rhabdomyosarcoma (RMS 2005): a multicentre, open-label,
randomised, phase 3 trial. Lancet Oncol 2019;20:1566-1575.
- Kerbel RS, Shaked Y. Therapy-activated stromal cells can dictate tumor
fate. J Exp Med 2016;213:2831-2833.
- Saiki-Craghill S. The children’s sentinels: mothers and their
relationships with health professionals in the context of Japanese
health care. Soc Sci Med 1997;44:291-300.
- Mayer DK, Parsons SK, Terrin N, et al. School re-entry after a cancer
diagnosis: physician attitudes about truth telling and information
sharing. Child Care Health Dev 2005;31:355-63.
- Senerchia A, Macedo CR, Ferman S, et al. Results of a randomized,
prospective clinical trial evaluating metronomic chemotherapy in
nonmetastatic patients with high-grade, operable osteosarcomas of the
extremities: A report from the Latin American Group of Osteosarcoma
Treatment. Cancer 2017;123:1003-1010.
- Minard-Colin V, Ichante JL, Nguyen L, et al. Phase II study of
vinorelbine and continuous low doses cyclophosphamide in children and
young adults with a relapsed or refractory malignant solid tumour:
Good tolerance profile and efficacy in rhabdomyosarcoma – A report
from the Societe Francaise des Cancers et leucemies de l’Enfant et de
l’adolescent (SFCE). Eur J Cancer 2012;48:2409-2416.
- Choi DK, Helenowski I, Hijiya N, et al. Secondary malignancies in
pediatric cancer survivors: perspectives and review of the literature.
Int J Cancer 2014;135:1764-1773.
- GröbnerSN, Worst BC, Weischenfeldt J, et al. The landscape of genomic
alterations across childhood cancers. Nature 2018;555:321-327.
- Simon T, Hero B, Faldum A, et al. Long term outcome of high-risk
blastoma patients after immunotherapy with antibody ch14.18 or oral
metronomic chemotherapy. BMC Cancer 2011;11:21.